



6 April 2020

**OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")**

**VISITECT® CD4 Advanced Disease evaluation in
Malawi, Zimbabwe and the Democratic Republic of Congo**

Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing notes the publication on 3 April 2020 of the two phased diagnostic accuracy and feasibility-of-use evaluation study, conducted in Médecins Sans Frontières (MSF) supported health facilities in Malawi, Zimbabwe and the Democratic Republic of Congo.

The evaluation, led by Zibusiso Ndlovu of MSF's Southern Africa Medical Unit in Cape Town, South Africa concluded that Omega's VISITECT® CD4 Advanced Disease lateral flow assay is a promising test for decentralised CD4 screening in resource-limited settings, without access to CD4 testing and it can trigger prompt management of patients with Advanced HIV Disease.

The full research articles can be accessed from the following weblink:

<https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0230453&type=printable>

Contacts:

Omega Diagnostics Group PLC

Bill Rhodes, Interim Non-Executive Chairman
Colin King, Chief Executive
Kieron Harbinson, Group Finance Director

Tel: 01259 763 030

www.omegadiagnostics.com

finnCap Ltd

Geoff Nash/Hannah Boros (Corporate Finance)
Camille Gochez (ECM)

Tel: 020 7220 0500

Walbrook PR Limited

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or omega@walbrookpr.com

Mob: 07980 541 893

Mob: 07584 391 303